Tudriqev's Director-Level Override: Accelerated Approval Built on Contested Single-Arm Data With a 2030 Verdict

FDA Overrules Reviewers for Replimune's Melanoma Drug Approval

A director at the Center for Biologics Evaluation and Research overruled a team of FDA reviewers last month to hand Replimune an accelerated approval for the advanced melanoma therapy Tudriqev. This decision came despite the primary review team's recommendation to reject the drug for the third time, citing Replimune's failure to address deficiencies from previous complete response letters, particularly concerning the single-arm IGNYTE study. The approval was heavily influenced by a supportive 10-3 advisory committee vote in July, which acknowledged "messy" data but emphasized the importance of specialist input. The FDA granted approval with the explicit expectation that Replimune verifies Tudriqev's clinical benefit in the ongoing Phase 3 confirmatory trial, IGNYTE-3, with topline data anticipated in September 2030.

• The FDA's primary review team had agreed to reject Tudriqev for the third time, following denials in July 2025 and April. Reviewers found Replimune had not sufficiently addressed key deficiencies from prior complete response letters, specifically noting concerns with the single-arm IGNYTE study's data package regarding evidence of effectiveness.
• A senior director at CBER overruled the review team's recommendation, granting accelerated approval for Tudriqev. This decision was significantly influenced by a 10-3 supportive vote from an advisory committee in July, which, despite acknowledging "messy" data, provided crucial expert input that factored into the regulatory flexibility exercised under the accelerated approval pathway.
• The accelerated approval for Tudriqev comes with a full acknowledgment of remaining uncertainties and an explicit expectation for Replimune to verify the drug's clinical benefit. This verification is to be achieved through the ongoing Phase 3 confirmatory trial, IGNYTE-3, which is currently enrolling patients and expects to release topline data in September 2030.

The Persistent Challenges in Advanced Melanoma Treatment

Despite meaningful advances in immunotherapy and targeted therapy, a substantial proportion of patients with advanced melanoma face limited options after progressing on anti-PD-1-based regimens. The therapeutic landscape in this setting is constrained by high rates of primary and secondary resistance, modest efficacy of available salvage strategies, and compounding clinical factors that further narrow treatment choices.

• High rates of primary and secondary resistance to anti-PD-1 therapy: Approximately 40%–55% of patients with metastatic melanoma have primary resistance and do not initially respond to anti-PD-1, and an additional 25% of patients develop secondary resistance, exhibiting an initial response followed by disease progression. In registry data, 73% of patients progressing on first-line immune checkpoint inhibition (ICI) presented with primary PD-1-resistant disease, with a median progression-free survival (PFS) on ICI of only 2.6 months (95% CI 2.2–2.9).

• Limited efficacy of salvage immunotherapy strategies: In patients who progress on anti-PD-1, re-exposure or escalation with ICI yields minimal benefit. Addition of ipilimumab, relatlimab (anti-LAG3), or lenvatinib (VEGFR TKI) has "minimal to modest efficacy" in PD-1-refractory melanoma. Among 23 patients who received third-line ICI after progression on targeted therapy, only two showed an objective response.

• Modest and variable outcomes with BRAF/MEK inhibition after ICI failure: For BRAF-mutant patients, switching to combined BRAF plus MEK inhibition after ICI progression yields an objective response rate (ORR) of 42.6% and a disease control rate (DCR) of 55.6%, with a median PFS of 6.6 months (95% CI 5.4–7.8) and median OS of 16.0 months (95% CI 11.2–20.8). Outcomes are further diminished in patients with brain metastases, where ORR falls to 31.4% and DCR to 43.1%, compared with 52.6% and 66.7%, respectively, in those without brain metastases.

• Reduced efficacy of BRAF/MEK inhibition following prior BRAF inhibitor monotherapy: In patients who previously received a BRAF inhibitor and then received dabrafenib plus trametinib, confirmed ORRs were only 15% (95% CI, 4% to 35%) and 13% (95% CI, 5% to 27%) in two study parts, with a median PFS of 3.6 months (95% CI, 2 to 4) and median OS of 11.8 months (95% CI, 8 to 25) from cross-over. Patients who progressed rapidly on prior BRAF inhibitor monotherapy (less than 6 months) had an ORR of 0% (95% CI, 0% to 15%) with the combination.

• Toxicity burden limiting combination salvage regimens: When ipilimumab plus nivolumab (IPI+PD1) is used after BRAF/MEK inhibitor therapy, the rate of grade 3 or 4 toxicities is 31%, compared with 7% with PD1 monotherapy, constraining the use of more intensive combination approaches in a population that may already be clinically compromised.

• Adverse baseline prognostic features narrowing treatment eligibility: In the post-BRAF/MEK inhibitor setting, patients receiving IPI+PD1 had worse baseline characteristics, including higher rates of AJCC M1C/M1D stage (94%), progressing brain metastases (57%), and ECOG PS ≥1 (44%). ECOG PS ≥1, progressing brain metastases, and presence of bone metastases were identified as predictors of primary progression on subsequent immunotherapy (AUC=0.67).

• Emerging but still limited cell-based therapeutic options: Lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy recently approved by the FDA, demonstrates durable response in "approximately 30%" of heavily pretreated patients with metastatic melanoma who failed standard ICI and targeted therapy, representing a meaningful but partial solution to the unmet need in this population.

Tudriqev's Clinical Profile and Accelerated Approval Journey

Several recent studies have examined treatment strategies for patients with advanced melanoma who experienced disease progression on anti-PD-1 therapy, spanning both immune checkpoint inhibitor combinations and adoptive cell therapy approaches.

The phase 3 multicenter open-label trial "Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma" (ClinicalTrials.gov number NCT02278887) evaluated tumor-infiltrating lymphocyte (TIL) therapy versus ipilimumab (3 mg per kilogram of body weight) in 168 patients with unresectable stage IIIC or IV melanoma, 86% of whom had disease refractory to anti-programmed death 1 treatment. In the intention-to-treat population, median progression-free survival was 7.2 months (95% CI, 4.2 to 13.1) in the TIL group versus 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001). Objective response rates were 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32), respectively, and median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group versus 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs — driven mainly by chemotherapy-related myelosuppression — and in 57% of those who received ipilimumab.

A systematic review and meta-analysis titled "Efficacy and Safety of Immune Checkpoint Inhibitors in Advanced Melanoma Patients with Anti-PD-1 Progression" (2021) pooled data from 14 studies involving 1,460 patients treated with ipilimumab, nivolumab/ipilimumab combination, or anti-PD-1 retreatment following progression. Combination therapy yielded the highest pooled objective response rate at 23.08% (95% CI: 16.75% to 30.03%), while ipilimumab monotherapy produced a pooled objective response rate of 8.19% (95% CI: 5.78% to 10.92%). Survival outcomes in the ipilimumab cohort were inferior to those observed in anti-PD-1-naive patients, with median overall survival ranging from 5.1 to 7.4 months. Grade 3/4 immune-related adverse events in the ipilimumab cohort were estimated at 43.77% (95% CI 22.55% to 66.19%). A separate real-world multicenter retrospective study by the Turkish Oncology Group in BRAF-negative metastatic melanoma patients progressing on nivolumab reported objective response rates of 29.9% with chemotherapy and 32.4% with immunotherapy-based regimens post-progression, with complete response rates higher in the immunotherapy group (21.2% vs. 3.0%), though median progression-free survival (4.17 months vs. 3.9 months; p = 0.403) and median overall survival (7.83 months vs. 8.17 months; p = 0.416) did not differ significantly between the two groups.

Integrating Tudriqev into the Evolving Melanoma Landscape

For patients with advanced melanoma who have progressed on anti-PD-1 therapy, the past several years have seen meaningful, if still limited, advances across multiple therapeutic modalities. In PD-1-refractory melanoma, the addition of ipilimumab, relatlimab, or lenvatinib has demonstrated minimal to modest efficacy. Switching to targeted BRAF/MEK inhibition improves survival for BRAF-mutant disease, with combinations such as encorafenib plus binimetinib and dabrafenib plus trametinib representing established options for patients harboring BRAF V600E or V600K mutations. Real-world data from Japan confirm that both dabrafenib plus trametinib and encorafenib plus binimetinib show similar efficacy, with an overall response rate of 79.8%, median progression-free survival of 13.7 months, and median overall survival of 32.9 months. Notably, switching directly to another targeted therapy after progressive disease showed no clinical response; however, rechallenge followed by immune checkpoint inhibitor therapy showed a certain response.

Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has emerged as a clinically meaningful option in this refractory setting. In a cohort of patients with metastatic melanoma who had progressed on anti-programmed cell death protein 1 (anti-PD-1), an objective response rate of 32% was achieved with TIL therapy, including durable responses, though median progression-free survival was reduced in this anti-PD-1 refractory population. Lifileucel, a personalized autologous TIL therapy, has since received U.S. Food and Drug Administration approval as a second-line option, demonstrating durable response of approximately 30% in heavily pretreated metastatic melanoma. Investigational approaches including novel engineered oncolytic viral therapies and human leukocyte antigen (HLA)-restricted immune-mediated T-cell therapies are also showing promising clinical benefit in ongoing clinical trials.

Combination and locoregional strategies have also been explored. The CATAP protocol — combining cryoablation with transarterial infusion of pembrolizumab — demonstrated an overall response rate of 26.7% (95% confidence interval 4.3–49.0%) in melanoma patients with liver metastases, with clinical response observed in 2 of 6 patients (33.3%) who had failed first-line intravenous pembrolizumab treatment, and no grade 3–4 adverse events or major complications observed. Immunological correlates included a significant increase in CD3-CD16+CD56+ natural killer cells (P = 0.0124) and a marginally significant decrease in CD4+CD25+ regulatory T cells (P = 0.0546) three weeks after the first treatment cycle. Collectively, these data reflect a broadening therapeutic landscape for anti-PD-1-refractory advanced melanoma, spanning targeted therapy, adoptive cell transfer, and novel combination approaches.

A High-Stakes Accelerated Approval for Advanced Melanoma

The recent accelerated approval of Replimune's Tudriqev (RP1) for advanced melanoma patients who have progressed on anti-PD-1 therapy marks a pivotal, albeit complex, moment in oncology. For patients facing limited options after immune checkpoint blockade failure, this oncolytic immunotherapy offers a new beacon of hope, demonstrating deep and durable systemic responses in a challenging population. The clinical data from the IGNYTE study indicated an objective response rate of 32.9% with a median duration of response of 33.7 months, alongside a favorable safety profile primarily characterized by grade 1/2 adverse events. This represents a significant step forward, building on the legacy of oncolytic therapies pioneered by Replimune's co-founder, Robert Coffin, who previously developed T-VEC, the first FDA-approved therapy in this class.

However, the path to approval was not without its complexities. The FDA's decision to grant accelerated approval, overriding internal reviewer recommendations and acknowledging 'messy' data, highlights the agency's balancing act between patient need and data rigor. This regulatory flexibility, while beneficial for patients, places a substantial burden on Replimune. The company is now under immense pressure to definitively confirm Tudriqev's clinical benefit in the ongoing Phase 3 IGNYTE-3 trial, with topline data not expected until 2030.

This extended timeline for confirmatory data introduces several strategic considerations. Replimune must navigate the market with a conditionally approved product, potentially facing skepticism from clinicians and payers who may weigh the 'messy' initial data and the internal FDA dissent. Proactive communication and education will be crucial to foster confidence and drive adoption. Furthermore, the long wait for definitive Phase 3 results means the competitive landscape in advanced melanoma could evolve significantly, with new therapies potentially emerging. The success of IGNYTE-3 is paramount; its failure would not only jeopardize Tudriqev's market presence but could also impact future regulatory pathways for other innovative therapies seeking accelerated approval based on complex data sets. This approval, therefore, is not just a win, but a high-stakes commitment to future validation.